Viva Biotech and Pfizer Collab on Cardiovascular Treatment Initiative

Viva Biotech’s investment enterprise, Riparian Pharmaceuticals, works to develop cutting-edge treatments for cardiovascular conditions.

Riparian has recently revealed an exclusive deal with Pfizer on a research and licence contract.

“Riparian Pharmaceuticals works to develop cutting-edge treatments for cardiovascular conditions“

Pfizer will provide Riparian with sole access to one of their preclinical projects in return for advance payment and milestone rewards, in addition to royalties on the proceeds from any subsequent treatments.

As part of the deal, Pfizer will assist Riparian in finding which other molecules they should target in order to achieve vasoprotection.

Chief Scientific Officer of Viava, Dr. Zhixiong Ye, explained how “Viva has invested in Riparian since September 2018, and helped Riparian obtain a quality clinical candidate through professional leadership of a team of senior scientists.”

Chief Information Officer at the company, Dr. Han Dai, explained how a knowledgeable team and substantial business competencies meant that “Riparian ultimately accomplished the identification of a novel target and secured a clinical candidate.”

He continued: “The patent transfer and R&D collaboration with Pfizer further demonstrate the potential value of Riparian’s pipeline and are another successful case of Viva’s EFS business for licensing transactions.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

See all the latest jobs in Science